Flutemetamol

CHEMBL579205 Phase 4 승인됨 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
274.3 g/mol
LogP
3.8
Phase
4

This compound selectively binds to amyloid beta aggregates in brain tissue, used as part of PET imaging evaluation for Alzheimer's disease.

분자량

274.3200 g/mol

LogP

3.80

TPSA

73.40 Ų

리핀스키 5의 법칙

통과

치료 영역

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CNc1ccc(-c2nc3ccc(O)cc3s2)cc1F

InChI

InChI=1S/C14H11FN2OS/c1-16-11-4-2-8(6-10(11)15)14-17-12-5-3-9(18)7-13(12)19-14/h2-7,16,18H,1H3

Molecular Formula

C14H11FN2OS

HBD / HBA

2 / 5

회전 가능 결합

2

무거운 원자

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

This compound selectively binds to amyloid beta aggregates in brain tissue, used as part of PET imaging evaluation for Alzheimer's disease.

Yes, Flutemetamol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL579205. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 10107393. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.